According to the latest announcement of CDE, the clinical trial application for GNC-039 tetra-specific antibody injection submitted by Bailey Pharmaceutical has been accepted.
CDE's latest announcement is that a clinical trial application for GNC-039 ivy antibody injections submitted by Leigh Pharmaceuticals has been accepted.
According to the latest announcement of CDE, the application for clinical trial of gnc-039 four specific antibody injection submitted by Baili pharmaceutical was accepted.<br>